The pilot study on the treatment of epilepsy resistant to treatment with Nemos confirms the first, positive interim results in June 2010. Nemos of cerbomed GmbH is the first device wave transcutaneous electrical nerve stimulation . The study has produced positive indications for the safety, tolerability and efficacy, with verification of user-friendly t-VNS.Our results suggest that this program can be useful for the prevention of falls and rehabilitation in the community, such as senior centers, Dr. Andrea Trombetti, University Hospitals and Faculty of Medicine of Geneva, and colleagues wrote in their report , which was published online Nov. 22 in the journal Archives of Internal Medicine, the first printed edition of the publication in the next issue of the magazine.
VNS Therapy is an outpatient basis, performed by the patient. Nemos unit consists of an electrode stimulation and an ear to ear as the patient brings a listener ear and stimulates the branch of the vagus nerve through the skin. The VNS Cerbomed should offer a very attractive and beneficial to the current treatments and emerging VNS, other methods of nerve, surgery or drug treatments.
‘The result of the pilot study is another important milestone for our company. It encourages us to reach a global, multi-center study for the treatment of VNS is from the middle of the year, and laid the foundation stone for a launch of success, ‘said Prof. Dr.
Jens Ellrich, Medical Director of cerbomed
Comments are closed.